{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.2","upperLimit":"16.1","value":"10.8"},{"groupId":"OG001","lowerLimit":"1.7","upperLimit":"11.7","value":"4.5"},{"groupId":"OG002","lowerLimit":"3.5","upperLimit":"100.0","value":"20.0"},{"groupId":"OG003","lowerLimit":"13.4","upperLimit":"41.9","value":"23.7"},{"groupId":"OG004","lowerLimit":"5.7","upperLimit":"25.4","value":"12.0"},{"groupId":"OG005","lowerLimit":"11.4","upperLimit":"46.6","value":"23.1"},{"groupId":"OG006","lowerLimit":"18.4","upperLimit":"44.5","value":"28.6"},{"groupId":"OG007","lowerLimit":"9.8","upperLimit":"40.9","value":"20.0"},{"groupId":"OG008","lowerLimit":"33.4","upperLimit":"66.7","value":"47.2"},{"groupId":"OG009","lowerLimit":"56.5","upperLimit":"90.3","value":"71.4"},{"groupId":"OG010","lowerLimit":"41.6","upperLimit":"81.8","value":"58.3"}]}],"title":"Year 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"14.2","upperLimit":"25.4","value":"19.0"},{"groupId":"OG001","lowerLimit":"3.1","upperLimit":"14.6","value":"6.7"},{"groupId":"OG002","lowerLimit":"13.7","upperLimit":"100.0","value":"40.0"},{"groupId":"OG003","lowerLimit":"13.4","upperLimit":"41.9","value":"23.7"},{"groupId":"OG004","lowerLimit":"7.0","upperLimit":"27.8","value":"14.0"},{"groupId":"OG005","lowerLimit":"17.3","upperLimit":"54.8","value":"30.8"},{"groupId":"OG006","lowerLimit":"31.0","upperLimit":"59.2","value":"42.9"},{"groupId":"OG007","lowerLimit":"12.2","upperLimit":"44.6","value":"23.3"},{"groupId":"OG008","lowerLimit":"36.1","upperLimit":"69.3","value":"50.0"},{"groupId":"OG009","lowerLimit":"56.5","upperLimit":"90.3","value":"71.4"},{"groupId":"OG010","lowerLimit":"41.6","upperLimit":"81.8","value":"58.3"}]}],"title":"Year 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16.9","upperLimit":"28.7","value":"22.1"},{"groupId":"OG001","lowerLimit":"4.6","upperLimit":"17.4","value":"9.0"},{"groupId":"OG002","lowerLimit":"13.7","upperLimit":"100.0","value":"40.0"},{"groupId":"OG003","lowerLimit":"13.4","upperLimit":"41.9","value":"23.7"},{"groupId":"OG004","lowerLimit":"8.5","upperLimit":"30.2","value":"16.0"},{"groupId":"OG005","lowerLimit":"20.4","upperLimit":"58.7","value":"34.6"},{"groupId":"OG006","lowerLimit":"32.9","upperLimit":"61.2","value":"44.9"},{"groupId":"OG007","lowerLimit":"14.7","upperLimit":"48.3","value":"26.7"},{"groupId":"OG008","lowerLimit":"36.1","upperLimit":"69.3","value":"50.0"},{"groupId":"OG009","lowerLimit":"60.6","upperLimit":"92.9","value":"75.0"},{"groupId":"OG010","lowerLimit":"41.6","upperLimit":"81.8","value":"58.3"}]}],"title":"Year 3"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.4","upperLimit":"29.3","value":"22.6"},{"groupId":"OG001","lowerLimit":"4.6","upperLimit":"17.4","value":"9.0"},{"groupId":"OG002","lowerLimit":"13.7","upperLimit":"100.0","value":"40.0"},{"groupId":"OG003","lowerLimit":"13.4","upperLimit":"41.9","value":"23.7"},{"groupId":"OG004","lowerLimit":"8.5","upperLimit":"30.2","value":"16.0"},{"groupId":"OG005","lowerLimit":"20.4","upperLimit":"58.7","value":"34.6"},{"groupId":"OG006","lowerLimit":"32.9","upperLimit":"61.2","value":"44.9"},{"groupId":"OG007","lowerLimit":"14.7","upperLimit":"48.3","value":"26.7"},{"groupId":"OG008","lowerLimit":"36.1","upperLimit":"69.3","value":"50.0"},{"groupId":"OG009","lowerLimit":"60.6","upperLimit":"92.9","value":"75.0"},{"groupId":"OG010","lowerLimit":"41.6","upperLimit":"81.8","value":"58.3"}]}],"title":"Year 4"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.9","upperLimit":"29.8","value":"23.1"},{"groupId":"OG001","lowerLimit":"5.4","upperLimit":"18.8","value":"10.1"},{"comment":"In Part 2 subjects in CP3L and ADV treatment groups were only evaluated up to Year 4.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"In Part 2 subjects in CP3L and ADV treatment groups were only evaluated up to Year 4.","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"In Part 2 subjects in CP3L and ADV treatment groups were only evaluated up to Year 4.","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"In Part 2 subjects in CP3L and ADV treatment groups were only evaluated up to Year 4.","groupId":"OG005","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"In Part 2 subjects in CP3L and ADV treatment groups were only evaluated up to Year 4.","groupId":"OG006","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"In Part 2 subjects in CP3L and ADV treatment groups were only evaluated up to Year 4.","groupId":"OG007","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"In Part 2 subjects in CP3L and ADV treatment groups were only evaluated up to Year 4.","groupId":"OG008","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"In Part 2 subjects in CP3L and ADV treatment groups were only evaluated up to Year 4.","groupId":"OG009","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"In Part 2 subjects in CP3L and ADV treatment groups were only evaluated up to Year 4.","groupId":"OG010","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}],"title":"Year 5"}],"denoms":[{"counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"89"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"38"},{"groupId":"OG004","value":"50"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"49"},{"groupId":"OG007","value":"30"},{"groupId":"OG008","value":"36"},{"groupId":"OG009","value":"28"},{"groupId":"OG010","value":"24"}],"units":"Participants"}],"description":"The cumulative incidence of on-treatment progression or death adjusting for the competing risk of treatment discontinuation without the event. Disease progression was determined by the investigator as the reason for treatment discontinuation and death was due to any cause within 30 days of last dose. Duration in months = (date of PD/death or last valid cytogenetic/hematologic assessment if censored - first dose date)/30.4. 95% confidence intervals were calculated using Gray's method.\n\nNA = not estimable. One year = 12 months.","dispersionType":"95% Confidence Interval","groups":[{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP2L IM-R CML; who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM.","id":"OG000","title":"Bosutinib 500 mg, CP2L-CML IM-R (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP2L IM-I CML; who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM.","id":"OG001","title":"Bosutinib 500 mg, CP2L-CML IM-I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP3L IM R/I, D and NI R/I or IM R/I and NI-I CML.","id":"OG002","title":"Bosutinib 500 mg, CP3L-CML IM R/I, (D+NI) R/I or NI-I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP3L IM R/I and D-R CML.","id":"OG003","title":"Bosutinib 500 mg, CP3L-CML IM R/I + D-R (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP3L IM R/I and D-I CML.","id":"OG004","title":"Bosutinib 500 mg, CP3L-CML IM R/I + D-I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with CP3L IM R/I and NI-R CML.","id":"OG005","title":"Bosutinib 500 mg, CP3L-CML IM R/I + NI-R (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with AP IM R/I CML; who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM.","id":"OG006","title":"Bosutinib 500 mg, AP-CML IM R/I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with AP Multi-TKI: IM, D and/or NI R/I CML.","id":"OG007","title":"Bosutinib 500 mg, AP-CML Multi-TKI R/I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with BP IM R/I CML ; who had no prior proto-oncogene tyrosine-protein kinase Src, Abl, or Src-Abl inhibitor exposure other than IM.","id":"OG008","title":"Bosutinib 500 mg, BP-CML IM R/I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with BP Multi-TKI: IM, D and/or NI R/I CML.","id":"OG009","title":"Bosutinib 500 mg, BP-CML Multi-TKI R/I (Part 2)"},{"description":"Bosutinib 500 mg was administered orally once-daily in participants with Ph+ ALL","id":"OG010","title":"Bosutinib 500 mg, Ph+ ALL (Part 2)"}],"paramType":"NUMBER","populationDescription":"All-treated population included all enrolled participants who received at least one dose of study medication.","reportingStatus":"POSTED","timeFrame":"Years 1, 2, 3, 4, and 5 (CP2L only)","title":"Cumulative Incidence of Progression/Death - Part 2","type":"SECONDARY","unitOfMeasure":"percentage of participants"}